{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:05:36Z","timestamp":1791230736614,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hyperuricemia, characterized by elevated serum uric acid (UA) levels, is associated with cardiovascular\u2013kidney\u2013metabolic syndrome and remains challenging to manage due to medication side effects and adherence issues. SGLT2 inhibitors (SGLT2i), primarily prescribed for diabetes (DM), heart failure (HF), and chronic kidney disease (CKD), have demonstrated potential UA-lowering effects, though their precise impact is not well established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter retrospective cohort study used a pre-and-post analysis to evaluate the effect of SGLT2i on UA levels. Data were collected from four major healthcare centers in Saudi Arabia. The study included adult patients who initiated SGLT2i therapy between January 2022 and January 2024, excluding those with active gout flares, a history of cancer, or recent changes in UA-lowering therapy. The primary outcome was the percentage change in serum UA levels post- i initiation, with secondary outcomes including subgroup analyses, metabolic effects, univariate and multivariate modeling, and longitudinal trend evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 2,400 patients screened, 454 were included in the final analysis. SGLT2i significantly reduced UA levels by 4.5% (p=0.006), with the most pronounced reduction in patients with baseline elevated UA (10%, p=0.001) and those with HF (9%, p=0.001). Univariate analysis identified DM &amp;amp; HF, DM &amp;amp; CKD, and DM, HF &amp;amp; CKD as predictors of response, but multivariate analysis confirmed only DM &amp;amp; HF as an independent predictor (OR\u00a0=\u00a02.2, 95% CI: 1.2\u20134.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings suggest that SGLT2i may serve as an adjunct therapy for hyperuricemia, especially in patients with DM &amp;amp; HF, highlighting the need for further research on long-term benefits.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1667438","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:35Z","timestamp":1760933675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ehsan A.","family":"Habeeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Ghaith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed M.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghalia","family":"Aquil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa H.","family":"Afana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Alqarafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A.","family":"Alahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar S.","family":"Alkhezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1038\/s41598-018-22662-5","article-title":"Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China","volume":"8","author":"Song","year":"2018","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000076","article-title":"Hyperuricemia in Saudi Arabia","volume":"20","author":"Al-Arfaj","year":"2001","journal-title":"Rheumatol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu Rev Physiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct083","article-title":"Independent and conjoint associations of gout and hyperuricemia with total and cardiovascular mortality","volume":"106","author":"Stack","year":"2013","journal-title":"QJM"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24612","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis","volume":"61","author":"Kim","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1286206","article-title":"Interaction between anemia and hyperuricemia in the risk of all-cause mortality in patients with chronic kidney disease","volume":"15","author":"Lu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.69.8.594","article-title":"Asymptomatic hyperuricemia: to treat or not to treat","volume":"69","author":"Dincer","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3825-0","article-title":"Asymptomatic hyperuricemia: is it time to intervene","volume":"36","author":"Paul","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B13","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer","year":"2014","journal-title":"Am Fam Physician"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211016619","article-title":"Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis","volume":"13","author":"Sharma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure: JACC review topic of the week","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B18","unstructured":"Philadelphia, PA\n          American Board of Internal Medicine\n          Uric acid levels and management guidelines\n          \n          2022"},{"key":"B19","first-page":"27","article-title":"NSAID use in patients with rheumatic disease: a review of benefits and risks","author":"Papatheodorou","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B20","first-page":"299","article-title":"The management of gout: much has changed","volume":"45","author":"Robinson","year":"2016","journal-title":"Aust Fam Physician"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.63","article-title":"Reduced glomerular filtration rate increases serum uric acid concentrations: effect of dose-response relationship in the US general population","volume":"82","author":"Krishnan","year":"2012","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0241-z","article-title":"Regulation of uric acid excretion by the kidney","volume":"14","author":"Lipkowitz","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"B25","first-page":"23","article-title":"Prevalence and risk factors of chronic kidney disease in type 2 diabetes in Saudi Arabia","volume":"33","author":"Alqarni","year":"2022","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/eurheartj\/ehi022","article-title":"The prevalence of heart failure in patients with diabetes: insights from the Reykjavik Study","volume":"26","author":"Thrainsdottir","year":"2005","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042360","article-title":"Association of diabetes mellitus with heart failure and chronic kidney disease: results from the CANVAS Program","volume":"141","author":"McGuire","year":"2020","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50205","article-title":"Association between cardiovascular disease and chronic kidney disease prevalence and characteristics in Saudi Arabia","volume":"15","author":"Elheet","year":"2023","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.endinu.2024.06.004","article-title":"Reducing hyperuricemic events with SGLT2 inhibitors: an updated systematic review with meta-regression","volume":"72","author":"Ghukasyan","year":"2025","journal-title":"Endocrinol Diabetes Nutr"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35353","article-title":"Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan","volume":"4","author":"Chung","year":"2021","journal-title":"JAMA NetwOpen"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.33267","article-title":"Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes","volume":"6","author":"Wei","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00468.2018","article-title":"SGLT2 inhibition and renal uric acid excretion: role of glucose and sodium transporters","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12270","article-title":"Allopurinol use and cardiovascular outcomes in patients with hypertension: a population-based cohort study","volume":"73","author":"MacIsaac","year":"2019","journal-title":"Hypertension"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010021","article-title":"Medium- and long-term effects of dapagliflozin on serum uric acid level in patients with type 2 diabetes: a real-world study","volume":"13","author":"Wang","year":"2022","journal-title":"J Pers Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1667438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:14:36Z","timestamp":1760933676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1667438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":40,"alternative-id":["10.3389\/fendo.2025.1667438"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1667438","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1667438"}}